President Donald Trump has signed an executive order that may impose tariffs of up to 100% on certain patented drugs. This policy targets companies that fail to negotiate agreements with the administration in the coming months. The executive order aims to curb the import of pharmaceuticals considered a threat to national security.
Key Details of the Executive Order
Companies that enter a “most favoured nation” pricing deal and establish manufacturing facilities in the United States will face a 0% tariff. Those without a pricing agreement but actively building in the U.S. will incur a 20% tariff, which could increase to 100% within four years.
Timeframe for Negotiations
- 120 days for larger companies to negotiate.
- 180 days for smaller firms.
A senior administration official confirmed that companies have several months to reach agreements before tariffs are enforced. Currently, 17 pricing deals have been negotiated with drugmakers, with 13 formalized agreements.
Background and Implications
Trump’s action coincides with the anniversary of his previous tariffs introduced last year, known as “Liberation Day.” While these earlier tariffs were later overturned by the Supreme Court, they marked a significant shift in U.S. trade policy.
Concerns have been raised regarding the potential adverse effects of new tariffs. Stephen J. Ubl, CEO of PhRMA, cautioned that these taxes on innovative medicines could lead to increased costs and threaten billions in U.S. investments.
International Agreements and Tariffs
Several countries have reached trade agreements with the U.S. that set specific drug tariff rates:
- EU, Japan, Korea, and Switzerland: 15% tariff on patented drugs.
- UK: Initially a 10% tariff, which may decrease to 0% under future agreements.
Other Tariff Updates
On the same day, Trump announced changes to tariffs on imported metals. Tariffs on steel, aluminum, and copper will remain at 50% but will be calculated based on the full customs value, preventing avoidance of higher payments. Derivative metal products will also see adjusted tariff calculations based on their metal composition.
Future of Sector-Specific Tariffs
These recent tariffs reflect Trump’s ongoing strategy of employing sector-specific import taxes. His administration continues to utilize Section 232 of the Trade Expansion Act, paving the way for additional product-specific tariffs.
Although many states have challenged the new tariffs, Trump maintains that they are vital for restoring U.S. wealth, reducing the trade deficit, and revitalizing domestic manufacturing.
As the global supply chain faces disruptions, businesses and households are already feeling the weight of rising prices exacerbated by these tariff strategies.
